Bristol-Myers Squibb (BMY)

AI-powered earnings call analysis for Bristol-Myers Squibb. Get insights from quarterly earnings reports with our AI-generated podcast. Educational content only - not investment advice.

20 episodes 5 languages

Latest Episode

Q3 2026 Earnings

6:32 • 10/29/2026

Bristol-Myers Squibb (BMY) - Q3 2026

0:00

6:32

Speed:

Q3 2026 Earnings

6:01 • 2026/10/29

Bristol-Myers Squibb (BMY) - Q3 2026

0:00

6:01

Speed:

Q3 2026 Earnings

9:22 • 29/10/2026

Bristol-Myers Squibb (BMY) - Q3 2026

0:00

9:22

Speed:

Q3 2026 Earnings

7:34 • 29/10/2026

Bristol-Myers Squibb (BMY) - Q3 2026

0:00

7:34

Speed:

Q3 2026 Earnings

6:24 • 29.10.2026

Bristol-Myers Squibb (BMY) - Q3 2026

0:00

6:24

Speed:

All Episodes

EN - English (4) CN - 中文 (4) FR - Français (4) ES - Español (4) DE - Deutsch (4)

Q3 2026 Earnings

6:32

Bristol-Myers reported 7% Q3 revenue growth to $13.1B, growth portfolio +12% to $7.7B, announced positive late-stage pipeline results, and raised full-year EPS guidance to $6.35-$6.55.

Q2 2026 Earnings

6:51

Bristol-Myers Squibb delivered strong Q2 with $13B revenue (+5%) driven by growth portfolio reaching 60% of sales (+14%), while raising 2026 guidance and advancing pipeline toward 10+ new medicines by decade end.

Q1 2026 Earnings

7:45

Bristol-Myers Squibb delivered solid Q1 2026 with $11.5B revenue (+1% YoY) and growth portfolio sales of $6.2B (+9%), driven by Eliquis and cell therapy, while advancing a diversified pipeline with multiple late-stage catalysts expected in late 2026.